Therapy Watch Prostate Cancer (PCa) launches this month
With second generation hormonal agents now beginning to be used in earlier stages of treatment, pharma market researchers require in-depth insights into the PCa market in order to measure the impact of new treatments as they launch.
Available to purchase now, Therapy Watch PCa provides real-time insights into key patient segments, hormonal treatment paradigms and treatment drivers, enabling you to identify key insights ahead of the competition and drive your marketing strategy.
Strengthening brand perception through real-time insights from ophthalmologists at conference
Our client wished to conduct conference research to evaluate reactions to their ophthalmic technology as a result of a new product launch, to measure awareness of their other portfolio of products within ophthalmology and see how they compared to competitors.
They particularly wanted to gather feedback and interest from physicians attending the conference in real-time as well as measure recall of their products.
Market Insights Can Deliver a Better Patient Experience
Published in eyeforpharma 27 March 2014 by Mary Assimakopoulos
Our team has been conducting a great deal of patient journey research lately. Having been in the market research business for oh, too many years, I am excited about the level of discussion between clients and agencies that there is currently around what is really important to patients and caregivers as an inroad to successful marketing.
Janssen publishes diabetes research conducted by Research Partnership
Janssen have published a report and call to action called “Diabetes in the Downturn” incorporating market research conducted by Research Partnership.
Janssen have published a report and call to action called “Diabetes in the Downturn” incorporating market research conducted by Research Partnership. The report provides an in-depth look at the impact of the recent economic downturn on diabetes management in six European countries. It offers perspectives from both patients and general practitioners and reveals the additional stresses associated with trying to manage type 2 diabetes during a time of global fiscal pressure.
Excellence in oncology
Developing an effective biomarker strategy
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers, physicians and patients. Payers are able to demonstrate that the treatment they are paying for will be of maximum value. Physicians feel confident that they are offering an effective drug, which is at the cutting-edge of medicine. And patients clearly benefit from a treatment programme that reduces the risk of unnecessary toxicities and offers them better outcomes.